Ipsen SA

119,10

10-января-25 11:28:52

15 мин. задержка

Акции

+0,15

+0,13%

Сегодняшний диапазон

118,10 - 119,10

ISIN

FR0010259150

Источник

Cboe

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 янв 2025 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen - Half year statement - 2024 12 31

07 янв 2025 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 дек 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology

03 дек 2024 01:00:00 Источник Nasdaq GlobeNewswire
Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

15 ноя 2024 11:00:00 Источник Nasdaq GlobeNewswire
Ipsen - October 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 ноя 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

23 окт 2024 01:00:00 Источник Nasdaq GlobeNewswire
Ipsen receives its second Shingo Prize for operational excellence

14 окт 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09 окт 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease

23 сен 2024 07:13:10 Источник Nasdaq GlobeNewswire
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade

20 сен 2024 08:57:57 Источник Nasdaq GlobeNewswire
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

16 сен 2024 08:45:00 Источник Nasdaq GlobeNewswire
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

15 сен 2024 08:45:00 Источник Nasdaq GlobeNewswire
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

04 сен 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024

13 авг 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024

06 авг 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

05 авг 2024 12:00:00 Источник Nasdaq GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024

30 июл 2024 12:00:00 Источник Nasdaq GlobeNewswire
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

26 июл 2024 06:46:22 Источник Nasdaq GlobeNewswire
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

25 июл 2024 08:18:23 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.